Artiva Biotherapeutics, Inc.
As of Oct 22, 2026, Artiva Biotherapeutics is in Stage 3, the topping phase, now in week 4 (since Sep 29, 2026). It closed at $6.20, 53.7% below its 52-week high and below its 200-day average, which is rising.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ARTV early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ARTV among Biotechnology106th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …106 | ARTV | Stage 3 · wk 4 | 83 | −19.7% |
Artiva Biotherapeutics: quick answers
What stage is Artiva Biotherapeutics in?
As of Oct 22, 2026, Artiva Biotherapeutics (ARTV) is in Stage 3, the topping phase. It entered Stage 3 on Sep 29, 2026 and is in week 4. What the four stages mean
Is Artiva Biotherapeutics in an uptrend?
Its uptrend has stalled. Artiva Biotherapeutics is in Stage 3, the topping phase that follows an advance. It trades 22.7% below its 200-day average, which is rising.
How far is Artiva Biotherapeutics from its 52-week high?
Artiva Biotherapeutics closed at $6.20 on Oct 22, 2026, 53.7% below its 52-week high of $13.39. Its 52-week low is $3.07.
How has Artiva Biotherapeutics performed over the past year?
As of Oct 22, 2026, Artiva Biotherapeutics is up 42.2% over the past year and up 46.6% so far in 2026.
Which sector and industry is Artiva Biotherapeutics in?
Artiva Biotherapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.